Who are Sinusitis Hevert SL Tablet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Traumeel® / Zeel® Injectable Solution, Disci/Rhus toxicodendron comp.®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sinusitis-hevert-sl-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Sinusitis Hevert SL Tablet — Competitive Intelligence Brief

Sinusitis Hevert SL Tablet (Sinusitis Hevert SL Tablet) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Homeopathic combination remedy. Area: Otolaryngology / Respiratory.

marketed Homeopathic combination remedy Otolaryngology / Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Sinusitis Hevert SL Tablet (Sinusitis Hevert SL Tablet) — Hevert-Arzneimittel GmbH & Co. KG. Sinusitis Hevert SL is a homeopathic combination tablet that works through multiple plant and mineral extracts to reduce inflammation and support drainage in acute sinusitis.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Sinusitis Hevert SL Tablet TARGET	Sinusitis Hevert SL Tablet	Hevert-Arzneimittel GmbH & Co. KG	marketed	Homeopathic combination remedy
Traumeel® / Zeel® Injectable Solution	Traumeel® / Zeel® Injectable Solution	Biologische Heilmittel Heel GmbH	phase 3	Homeopathic combination remedy
Disci/Rhus toxicodendron comp.®	Disci/Rhus toxicodendron comp.®	Charite University, Berlin, Germany	phase 3	Homeopathic combination remedy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Homeopathic combination remedy class)

Biologische Heilmittel Heel GmbH · 1 drug in this class
Charite University, Berlin, Germany · 1 drug in this class
Hevert-Arzneimittel GmbH & Co. KG · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sinusitis Hevert SL Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/sinusitis-hevert-sl-tablet. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab